NRG-LU006

Open to Accrual

Return to Protocol Table

Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)

Principal Investigator

Andreas Rimner, MD

Status

Open to Accrual

Date Opened To Accrual

January 29 2020

Disease Site

Lung [LU]

Mesothelioma

Phase

III

Developmental Therapeutics

Primary Objective

To detect an improvement in overallsurvival with the addition of adjuvant hemithoracic IMPRINT to surgery andchemotherapy compared to surgery and chemotherapy alone.

Patient Population

Patients with pathologically (histologically or cytologically) confirmed diagnosis of epithelioid or biphasic MPM, amenable to MCR, within 90 days prior to Step 1 Registration

Target Accrual

150

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.